Literature DB >> 17896949

Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.

Jacqueline M Cale1, Daniel A Lawrence.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA, respectively). PAI-1 also interacts with non-proteinase targets such as vitronectin, heparin, and several endocytic receptors of the low-density lipoprotein-receptor family, including the low-density lipoprotein-receptor related protein (LRP) and the very low-density lipoprotein receptor (VLDLr). PAI-1 is a multifunctional protein that is not only a physiologic regulator of fibrinolysis and cell migration but is also associated with several acute and chronic pathologic conditions. PAI-1 is involved in the pathophysiology of renal, pulmonary, cardiovascular, and metabolic diseases, and in vitro experiments and animal studies have elucidated PAI-1's contribution to the physiology or pathology of some of these conditions. PAI-1 is normally present at low levels in plasma, but acute and chronic diseases are strongly associated with increased PAI-1 expression and release. At sites of vascular injury and inflammation, local PAI-1 levels are even higher, due to its concentration in extracellular matrix through association with vitronectin. Elevated local or systemic PAI-1 is not only a marker of disease; it can also exacerbate pathologic conditions. Thus, interventions that directly target PAI-1 may be useful for the treatment of a number of chronic and acute disorders. Typically, such interventional strategies would involve the identification of small molecule inhibitors of PAI-1, and several recent reviews have covered this topic. However, it may also be possible or even potentially advantageous, to exploit the diverse functional interactions of PAI-1 to create highly specific and targeted therapeutic agents based on the PAI-1 protein itself. To understand how PAI-1 could be developed as a therapeutic agent, it is first necessary to discuss its structural and functional characteristics in depth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17896949     DOI: 10.2174/138945007781662337

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  19 in total

1.  Morphine Withdrawal Increases Brain-Derived Neurotrophic Factor Precursor.

Authors:  Alessia Bachis; Lee A Campbell; Kierra Jenkins; Erin Wenzel; Italo Mocchetti
Journal:  Neurotox Res       Date:  2017-08-03       Impact factor: 3.911

2.  Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase.

Authors:  Anastasia M Makarova; Tatiana V Lebedeva; Taher Nassar; Abd Al-Roof Higazi; Jing Xue; Maria E Carinato; Khalil Bdeir; Douglas B Cines; Victoria Stepanova
Journal:  J Biol Chem       Date:  2011-05-03       Impact factor: 5.157

3.  Cyr61/CCN1 displays high-affinity binding to the somatomedin B(1-44) domain of vitronectin.

Authors:  Ivo M B Francischetti; Michalis Kotsyfakis; John F Andersen; Jan Lukszo
Journal:  PLoS One       Date:  2010-02-26       Impact factor: 3.240

4.  Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.

Authors:  Hua Fang; Veronica R Placencio; Yves A DeClerck
Journal:  J Natl Cancer Inst       Date:  2012-09-13       Impact factor: 13.506

Review 5.  The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases.

Authors:  Hunjoo Ha; Eun Y Oh; Hi B Lee
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

6.  Adenoviral overexpression and small interfering RNA suppression demonstrate that plasminogen activator inhibitor-1 produces elevated collagen accumulation in normal and keloid fibroblasts.

Authors:  Tai-Lan Tuan; Paul Hwu; Wendy Ho; Peter Yiu; Richard Chang; Annette Wysocki; Paul D Benya
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

7.  Plasminogen Activator Inhibitor-1 Reduces Tissue-Type Plasminogen Activator-Dependent Fibrinolysis and Intrahepatic Hemorrhage in Experimental Acetaminophen Overdose.

Authors:  Asmita Pant; Anna K Kopec; Kevin S Baker; Holly Cline-Fedewa; Daniel A Lawrence; James P Luyendyk
Journal:  Am J Pathol       Date:  2018-02-16       Impact factor: 4.307

8.  Tissue factor pathway inhibitor prevents airway obstruction, respiratory failure and death due to sulfur mustard analog inhalation.

Authors:  Raymond C Rancourt; Livia A Veress; Aftab Ahmad; Tara B Hendry-Hofer; Jacqueline S Rioux; Rhonda B Garlick; Carl W White
Journal:  Toxicol Appl Pharmacol       Date:  2013-05-30       Impact factor: 4.219

9.  Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.

Authors:  Christine R Schar; Jan K Jensen; Anni Christensen; Grant E Blouse; Peter A Andreasen; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2008-07-24       Impact factor: 5.157

10.  Diabetes-associated dysregulated cytokines and cancer.

Authors:  Yong Wu; Yanjun Liu; Yunzhou Dong; Jay Vadgama
Journal:  Integr Cancer Sci Ther       Date:  2016-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.